In the midst of renewed geopolitical tensions and fluctuating energy prices, global markets have shown mixed performance. While major indices like the Nasdaq and S&P 500 posted gains, small-cap stocks faced challenges with the Russell 2000 Index declining slightly by 0.61%, highlighting a cautious sentiment among investors towards smaller companies amid economic uncertainties. In this environment, identifying potentially undervalued small-cap stocks can involve looking for those with strong fundamentals and insider activity that may indicate confidence in their future prospects despite broader market volatility.
Top 10 Undervalued Small Caps With Insider Buying Globally
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| CellaVision | 23.9x | 4.4x | 45.13% | ★★★★★★ |
| Eurocell | 11.3x | 0.3x | 48.87% | ★★★★★☆ |
| Centurion | 11.8x | 4.0x | 33.82% | ★★★★★☆ |
| Natural Food International Holding | 11.5x | 1.2x | 6.93% | ★★★★☆☆ |
| Bilia | 16.2x | 0.3x | 40.57% | ★★★★☆☆ |
| Nexus Industrial REIT | 10.1x | 3.4x | 6.60% | ★★★★☆☆ |
| Pizza Pizza Royalty | 14.1x | 10.8x | 32.73% | ★★★☆☆☆ |
| Firan Technology Group | 40.4x | 3.0x | 19.30% | ★★★☆☆☆ |
| Chinasoft International | 20.7x | 0.4x | -2549.90% | ★★★☆☆☆ |
| CVS Group | 52.7x | 1.3x | 47.11% | ★★★☆☆☆ |
Below we spotlight a couple of our favorites from our exclusive screener.
China XLX Fertiliser (SEHK:1866)
Simply Wall St Value Rating: ★★★★☆☆
Overview: China XLX Fertiliser is engaged in the production and sale of fertilizers, such as urea and compound fertilizers, as well as chemicals like methanol and melamine, with a market capitalization of approximately CN¥5.68 billion.
Operations: The primary revenue streams are from Urea and Compound Fertilizer, generating CN¥9.71 billion and CN¥8.47 billion respectively, followed by Methanol at CN¥6.84 billion. The gross profit margin has shown fluctuations, recently recorded at 15.08% in September 2025 and 14.99% in December 2025, indicating variability over time. Operating expenses are a significant cost component, including sales & marketing and general & administrative expenses which contribute to the overall financial performance of the company.
PE: 11.4x
China XLX Fertiliser, a small-cap company, has recently seen insider confidence with Yunhua Yan purchasing 1.76 million shares for approximately RMB 17.2 million. Despite its lower profit margin of 3.7% compared to last year's 6.3%, the company approved a final dividend of RMB 0.32 per share for FY2025, showcasing commitment to shareholder returns amid challenges like high debt levels and reliance on external borrowing. Leadership changes include the appointment of Jeremy Cheah as CFO and Tan Wei Shyan as an independent director, potentially steering future growth in this dynamic sector where earnings are projected to grow by over 25% annually.
- Get an in-depth perspective on China XLX Fertiliser's performance by reading our valuation report here.
Understand China XLX Fertiliser's track record by examining our Past report.
Shanghai Haohai Biological Technology (SEHK:6826)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Shanghai Haohai Biological Technology is involved in the production and sale of biologics, specifically focusing on medical hyaluronic acid, with a market capitalization of CN¥11.36 billion.
Operations: The company generates revenue primarily from the production and sale of biologics, including medical hyaluronic acid, with recent revenue reaching CN¥2.40 billion. The gross profit margin was 68.29%, reflecting a significant portion of costs attributed to COGS and operating expenses.
PE: 13.4x
Shanghai Haohai Biological Technology, a company with smaller market capitalization, has seen its net profit margin decline from 15.6% to 9.8% over the past year, indicating potential financial challenges. Despite this, earnings are projected to grow at an annual rate of 23.52%, suggesting possible future strength. The recent board reshuffle and dividend affirmation underscore a commitment to shareholder value amidst these changes. With no insider confidence through share purchases reported recently, the focus remains on strategic leadership transitions for growth prospects ahead.
UltraGreen.ai (SGX:ULG)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: UltraGreen.ai focuses on providing advanced data systems and diagnostic solutions globally, with a market capitalization of $2.35 billion.
Operations: UltraGreen.ai generates revenue primarily from DxG - Americas and DxG - Rest of World, with smaller contributions from Ultralinq and UltraGreen Data System. The company's gross profit margin has shown an upward trend, reaching 84.86% by the end of 2025. Operating expenses include significant allocations towards general and administrative costs, which have increased over time.
PE: 26.7x
UltraGreen.ai, recently added to the S&P Global BMI Index, stands out in the small cap space with its strategic expansion into Southeast Asia following regulatory approval for Verdye in Singapore. This move enhances their fluorescence-guided surgery platform and aligns with their growth strategy. Insider confidence is evident as founder Ravinder Sajwan increased their stake by 335,200 shares for US$439K. The company has initiated a share repurchase program, indicating potential value recognition amidst forecasted earnings growth of 24% annually.
- Click here and access our complete valuation analysis report to understand the dynamics of UltraGreen.ai.
Review our historical performance report to gain insights into UltraGreen.ai's's past performance.
Next Steps
- Investigate our full lineup of 133 Undervalued Global Small Caps With Insider Buying right here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com